CBIO [NASD]
Catalyst Biosciences, Inc.
Index- P/E1.46 EPS (ttm)0.38 Insider Own0.10% Shs Outstand31.48M Perf Week0.00%
Market Cap17.14M Forward P/E- EPS next Y-0.36 Insider Trans0.00% Shs Float27.91M Perf Month-1.08%
Income11.90M PEG- EPS next Q-0.13 Inst Own25.00% Short Float / Ratio1.82% / 0.67 Perf Quarter7.29%
Sales3.20M P/S5.36 EPS this Y2.10% Inst Trans-3.71% Short Interest0.51M Perf Half Y67.37%
Book/sh0.93 P/B0.59 EPS next Y-140.00% ROA22.60% Target Price16.00 Perf Year85.15%
Cash/sh0.74 P/C0.74 EPS next 5Y- ROE26.90% 52W Range0.09 - 0.62 Perf YTD128.90%
Dividend- P/FCF- EPS past 5Y33.30% ROI-213.90% 52W High-11.29% Beta1.21
Dividend %- Quick Ratio18.40 Sales past 5Y79.00% Gross Margin-0.60% 52W Low497.59% ATR0.02
Employees45 Current Ratio18.40 Sales Q/Q- Oper. Margin- RSI (14)48.63 Volatility2.64% 4.57%
OptionableYes Debt/Eq0.00 EPS Q/Q80.70% Profit Margin- Rel Volume0.18 Prev Close0.55
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume759.08K Price0.55
Recom2.70 SMA20-0.19% SMA50-0.03% SMA20046.32% Volume135,752 Change0.00%
Apr-29-21Resumed Stephens Overweight $18 → $19
Feb-10-21Initiated Piper Sandler Overweight $15
May-21-20Initiated Raymond James Outperform $20
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Show Previous Ratings
Nov-16-22 05:05AM
Sep-19-22 09:43AM
Sep-01-22 04:05PM
Aug-25-22 08:00AM
Aug-23-22 07:11AM
08:00AM Loading…
Aug-19-22 08:00AM
Aug-15-22 04:05PM
Aug-11-22 06:00AM
Aug-10-22 12:46PM
Aug-03-22 08:00AM
Aug-01-22 08:30AM
07:30AM
Jul-22-22 12:21PM
Jul-19-22 08:00AM
Jul-14-22 09:40AM
08:00AM Loading…
Jul-06-22 08:00AM
Jun-29-22 08:00AM
Jun-28-22 09:40AM
May-26-22 11:03AM
May-23-22 09:57AM
08:30AM
May-09-22 08:30AM
Apr-08-22 09:57AM
Mar-31-22 08:00AM
Mar-15-22 05:00PM
Feb-17-22 08:00AM
Feb-03-22 05:38PM
Jan-25-22 08:00AM
Jan-12-22 12:00PM
Dec-20-21 07:51PM
11:59AM Loading…
Dec-11-21 11:59AM
Nov-22-21 08:00AM
Nov-12-21 09:54AM
09:24AM
07:00AM
Oct-29-21 08:00AM
Oct-28-21 03:05PM
Oct-13-21 04:05PM
Sep-28-21 04:01PM
Sep-24-21 08:00AM
Sep-17-21 07:06AM
Sep-15-21 08:00AM
Sep-09-21 08:00AM
Sep-08-21 08:00AM
Aug-05-21 10:55AM
08:00AM
Jul-29-21 03:05PM
Jul-22-21 08:00AM
Jul-19-21 04:01PM
02:09AM
Jul-14-21 08:00AM
Jul-06-21 08:00AM
Jul-01-21 08:00AM
Jun-28-21 08:45AM
08:00AM
Jun-21-21 06:00AM
Jun-10-21 08:00AM
May-20-21 02:57AM
May-18-21 08:00AM
May-13-21 08:00AM
May-06-21 12:19PM
09:23AM
09:15AM
08:00AM
May-05-21 12:29PM
08:00AM
Apr-28-21 08:00AM
Apr-21-21 11:43AM
Apr-19-21 08:00AM
Apr-12-21 08:00AM
Apr-07-21 04:05PM
Mar-21-21 04:20AM
Mar-04-21 08:00AM
Feb-18-21 08:00AM
Feb-11-21 04:01PM
Feb-10-21 10:05AM
Feb-03-21 08:00AM
Jan-29-21 04:01PM
Jan-27-21 08:00AM
Jan-26-21 04:04PM
Jan-20-21 08:00AM
Jan-19-21 11:46PM
Jan-15-21 08:00AM
Dec-15-20 10:28PM
Dec-07-20 08:00AM
Dec-03-20 04:02PM
08:50AM
Dec-02-20 08:00AM
Nov-30-20 10:44AM
10:42AM
Nov-25-20 10:15AM
Nov-24-20 04:01PM
Nov-12-20 08:50AM
Nov-11-20 07:57AM
Nov-05-20 09:00AM
08:00AM
Nov-03-20 08:00AM
Oct-14-20 10:17PM
10:29AM
08:00AM
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.